Clinical Trial Update: A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of ASP015K in rheumatoid arthritis patients with an inadequate response to DMARDs has completed, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ASP015K

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2020-03-16